Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Webby

Showing results (51-60 of 473) with videos related to

Pageof 48
Sort By:
Plos One|January 12, 2018
Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015Nipaporn Tewawong, Bindumadhav M Marathe, Yong Poovorawan, et al.
Influenza and Other Respiratory Viruses|July 9, 2017
Absence of clinical disease and contact transmission of HPAI H5NX clade 2.3.4.4 from North America in experimentally infected pigsBryan S Kaplan, Mia K Torchetti, Kelly M Lager, et al.
Viruses|June 24, 2022
Expanding Mouse-Adapted Yamagata-like Influenza B Viruses in Eggs Enhances In Vivo Lethality in BALB/c MiceMatthew J Pekarek, Erika M Petro-Turnquist, Adam Rubrum, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse modelPhilippe Noriel Q Pascua, Bindumadhav M Marathe, Peter Vogel, et al.
Antiviral Research|December 3, 2019
Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutionsPhilippe Noriel Q Pascua, Bindumadhav M Marathe, Shivantika Bisen, et al.
Plos One|November 1, 2011
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusGlendie Marcelin, Rebecca DuBois, Adam Rubrum, et al.
Antiviral Research|June 23, 2022
Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavirJeremy C Jones, Samuel W Rovito, Melissa K Penaflor, et al.
Influenza and Other Respiratory Viruses|July 18, 2017
Lineage-specific epitope profiles for HPAI H5 pre-pandemic vaccine selection and evaluationXueting Qiu, Venkata R Duvvuri, Jonathan B Gubbay, et al.
Nature Communications|February 19, 2026
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in miceKonstantin Andreev, Jeremy C Jones, Ahmed Kandeil, et al.
Journal of Pharmaceutical Sciences|October 21, 2010
PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studiesAlexander K Andrianov, Daniel P Decollibus, Alexander Marin, et al.
Pageof 48

Showing results (51-60 of 473) with videos related to

Sort By:
Pageof 48
Plos One|January 12, 2018
Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015Nipaporn Tewawong, Bindumadhav M Marathe, Yong Poovorawan, et al.
Influenza and Other Respiratory Viruses|July 9, 2017
Absence of clinical disease and contact transmission of HPAI H5NX clade 2.3.4.4 from North America in experimentally infected pigsBryan S Kaplan, Mia K Torchetti, Kelly M Lager, et al.
Viruses|June 24, 2022
Expanding Mouse-Adapted Yamagata-like Influenza B Viruses in Eggs Enhances In Vivo Lethality in BALB/c MiceMatthew J Pekarek, Erika M Petro-Turnquist, Adam Rubrum, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse modelPhilippe Noriel Q Pascua, Bindumadhav M Marathe, Peter Vogel, et al.
Antiviral Research|December 3, 2019
Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutionsPhilippe Noriel Q Pascua, Bindumadhav M Marathe, Shivantika Bisen, et al.
Plos One|November 1, 2011
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusGlendie Marcelin, Rebecca DuBois, Adam Rubrum, et al.
Antiviral Research|June 23, 2022
Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavirJeremy C Jones, Samuel W Rovito, Melissa K Penaflor, et al.
Influenza and Other Respiratory Viruses|July 18, 2017
Lineage-specific epitope profiles for HPAI H5 pre-pandemic vaccine selection and evaluationXueting Qiu, Venkata R Duvvuri, Jonathan B Gubbay, et al.
Nature Communications|February 19, 2026
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in miceKonstantin Andreev, Jeremy C Jones, Ahmed Kandeil, et al.
Journal of Pharmaceutical Sciences|October 21, 2010
PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studiesAlexander K Andrianov, Daniel P Decollibus, Alexander Marin, et al.
Pageof 48